Showing 7061-7070 of 8826 results for "".
- Dr. James Del Rosso Presents 'Medicine Chest' at Fall Clinicalhttps://practicaldermatology.com/news/dr-james-del-rossos-presents-medicine-chest-at-fall-clinical/2484096/A curated overview of skincare fundamentals, treatment pearls, and emerging data across acne, rosacea, hyperpigmentation, hidradenitis suppurativa (HS), and more was on display as James Q. Del Rosso, DO, presented “What’s New in the Medicine Chest” at the 2025 Fall Clinical Dermatology Conference
- Bullous Pemphigoid: The Time to Treat Is Now, Fall Clinical Speakers Sayhttps://practicaldermatology.com/news/bullous-pemphigoid-the-time-to-treat-is-now-fall-clinical-speakers-say/2484090/Earlier recognition of bullous pemphigoid (BP) is critical but safer, targeted treatment options are emerging for this aging and medically fragile patient population, according to a presentation from Donna Culton, MD, PhD, and Prince Adotama, MD, at the 2025 Fall Clinical Dermatology Conference.<
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other
- Arcutis Presents New ZORYVE Data in AD at Fall Clinical 2025https://practicaldermatology.com/news/arcutis-presents-new-zoryve-data-in-ad-at-fall-clinical-2025/2484062/Updates and new data sets from the INTEGUMENT trial program, including new quality-of-life and efficacy data for ZORYVE® (roflumilast) cream in pediatric and adult patients with atopic dermatitis (AD), were featured at the 2025 Fall Clinical Dermatology Conference
- ICONIC-TOTAL: Icotrokinra Shows Skin Clearance in Difficult-to-Treat PsO at 1 Yearhttps://practicaldermatology.com/news/iconic-total-icotrokinra-shows-skin-clearance-in-difficult-to-treat-pso-at-1-year/2484061/Icotrokinra, a novel oral IL-23 inhibitor, was associated with imporvements in plaque psoriasis in difficult-to-treat areas of the body, according to new data presented at 2025 Fall Clinical Dermatology Conference in Las Vegas.
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- Study: Ruxolitinib Cream Same or Better Than Triamcinolone for Mild to Moderate ADhttps://practicaldermatology.com/news/ruxolitinib-cream-triamcinolone-for-mild-to-moderate-ad/2483574/New analysis of phase 2 data indicates ruxolitinib cream 1.5% may offer comparable or superior efficacy to midpotency corticosteroid triamcinolone 0.1% cream in adult patients with long-standing mild to moderate atopic dermatitis (AD).
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://practicaldermatology.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res